Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(26 sites)
United States
University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla, California University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center, Orange, California University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California Florida Cancer Specialists and Research Institute, Lake Mary, Florida Northwest Cancer Centers, Dyer, Indiana The University of Kansas Cancer Center, Fairway, Kansas Dana-Farber Cancer Institute, Boston, Massachusetts Karmanos Cancer Institute, Detroit, Michigan University of Pennsylvania, Philadelphia, Pennsylvania The University of Texas MD Anderson Cancer Center, Houston, Texas Community Clinical Trials, Kingwood, Texas South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas UT Health San Antonio, San Antonio, Texas START Mountain Region, West Valley City, Utah Virginia Cancer Specialists, Fairfax, Virginia Australia
Macquarie University, Macquarie Park, New South Wales Tasman Health Care, Southport, Queensland Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia GenesisCare North Adelaide, North Adelaide, South Australia Eastern Health - Box Hill Hospital, Box Hill, Victoria Linear Clinical Research Ltd, Nedlands, Western Australia South Korea
Seoul National University Hospital, Seoul, Jongno-gu Severance Hospital, Seoul, Seodaemun-gu Korea University Anam Hospital, Seoul, Seongbuk-gu Seoul National University Bundang Hospital, Gyeonggi-do, Seongnam-si The Catholic University of Korea, St. Vincent's Hospital, Gyeonggi-do, Suwon-si